NCT06824454View on ClinicalTrials.gov

Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
HypophosphatemiaKidney Transplantation
Interventions
DRUG

Dipyridamole 75 MG

Dipyridamole administered three times daily when serum phosphorus levels fall below 4 mg/dL. The drug is used off-label for this study to manage hypophosphatemia in kidney transplant recipients.

Trial Locations (1)

94304

Stanford University, Stanford

All Listed Sponsors
lead

Stanford University

OTHER